Italia markets close in 1 hour 6 minutes

FTSE MIB
34.544,80
-280,21(-0,80%)
Dow Jones
39.861,45
+54,68(+0,14%)
Nasdaq
16.763,53
-31,34(-0,19%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
79,10
-0,70(-0,88%)
Bitcoin EUR
65.024,04
+3.350,52(+5,43%)

NVCR Sep 2024 10.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

11,00

0,00

(0,00%)

In data: 09:47AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in